GSK plc reported second-quarter earnings that surpassed analyst expectations, with turnover reaching £8.41 billion. The strong performance was driven by its Specialty Medicines and Vaccines divisions. In response to the results, the company's shares saw a notable increase in trading.
Alongside the positive earnings, GSK unveiled a substantial three-year restructuring program named "Accelerate Growth." The plan aims to achieve £1.9 billion in annual cost savings by 2029. These savings are intended to be reinvested into its late-stage drug pipeline and R&D to drive long-term growth and mitigate the impact of upcoming patent expirations for key drugs.